Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adherence to BCR-ABL inhibitors: issues for CML therapy.

Clinical lymphoma, myeloma & leukemia·2012

Same author

How I treat newly diagnosed chronic phase CML.

Blood·2012

Same author

Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.

Cancer·2012

Same author

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.

Clinical lymphoma, myeloma & leukemia·2012

Same author

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.

Clinical lymphoma, myeloma & leukemia·2012

Same author

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.

Cancer·2012

Search research articles

Related Experiment Video

Updated: Feb 24, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Immunotherapy based approaches in myelofibrosis.

Lucia Masarova¹, Srdan Verstovsek¹, Hagop Kantarjian¹

¹a MD Anderson Cancer Center , The University of Texas , Houston , TX , USA.

Expert Review of Hematology

|August 12, 2017

Summary

Immune-based therapies show promise for myelofibrosis (MF), addressing limited treatment options for anemia and fibrosis. Ongoing trials explore immunomodulatory drugs, antibodies, and checkpoint inhibitors to improve patient outcomes.

Keywords:

Myelofibrosis checkpoint inhibition immunomodulatory therapy interferon monoclonal antibodies

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Related Experiment Videos

Last Updated: Feb 24, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Area of Science:

Hematology
Immunology
Oncology

Background:

Myelofibrosis (MF) involves immune system dysregulation and increased pro-inflammatory cytokines, contributing to disease progression.
Current treatments for MF-related anemia, thrombocytopenia, and bone marrow fibrosis are limited, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

This review examines the potential of immune-based therapies for managing myelofibrosis.
It focuses on immunomodulatory imide drugs (IMiDs), interferons, monoclonal antibodies, targeted agents, and checkpoint inhibitors.

Main Methods:

A literature review was conducted using PubMed, Cochrane, Scopus, and clinicaltrials.gov.
The review synthesized data on the efficacy and application of various immune-based agents in MF.

Main Results:

Immunomodulatory imide drugs (IMiDs) like lenalidomide have shown efficacy in treating MF-associated cytopenias.
Interferon-alpha may benefit early-stage MF by impacting neoplastic bone marrow.
Monoclonal antibodies offer targeted cell death or T-cell activation by targeting tumor antigens or blocking inhibitory checkpoints.

Conclusions:

Immune-based therapies are under investigation for hematologic malignancies, with promising results in related cancers.
Further clinical trials combining these agents with targeted therapies and anti-fibrotic drugs will clarify their full potential in MF treatment.